Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Adler

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystoniaM F Brin, M F Lew, C H Adler, et al.
Neurology|December 28, 2006
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystoniaJ Jankovic, C Hunter, B Z Dolimbek, et al.
Neurology|May 16, 2002
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamicsK Kompoliti, C H Adler, R Raman, et al.
Dementia and Geriatric Cognitive Disorders|September 14, 2007
Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's diseaseM N Sabbagh, T Lahti, D J Connor, et al.
Neurology|October 27, 1997
Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patientsR J Uitti, R E Wharen, M F Turk, et al.
Neurology|April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ T Hutton, W C Koller, J E Ahlskog, et al.
Neurology|June 13, 2001
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremorM F Brin, K E Lyons, J Doucette, et al.
European Journal of Neurology|August 24, 2017
GBA mutations in Parkinson disease: earlier death but similar neuropathological featuresC H Adler, T G Beach, H A Shill, et al.
Neurology|June 10, 2009
Characterization of DCTN1 genetic variability in neurodegenerationC Vilariño-Güell, C Wider, A I Soto-Ortolaza, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystoniaM F Brin, M F Lew, C H Adler, et al.
Neurology|December 28, 2006
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystoniaJ Jankovic, C Hunter, B Z Dolimbek, et al.
Neurology|May 16, 2002
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamicsK Kompoliti, C H Adler, R Raman, et al.
Dementia and Geriatric Cognitive Disorders|September 14, 2007
Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's diseaseM N Sabbagh, T Lahti, D J Connor, et al.
Neurology|October 27, 1997
Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patientsR J Uitti, R E Wharen, M F Turk, et al.
Neurology|April 1, 1996
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's diseaseJ T Hutton, W C Koller, J E Ahlskog, et al.
Neurology|June 13, 2001
A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremorM F Brin, K E Lyons, J Doucette, et al.
European Journal of Neurology|August 24, 2017
GBA mutations in Parkinson disease: earlier death but similar neuropathological featuresC H Adler, T G Beach, H A Shill, et al.
Neurology|June 10, 2009
Characterization of DCTN1 genetic variability in neurodegenerationC Vilariño-Güell, C Wider, A I Soto-Ortolaza, et al.
Pageof 8